ANIX - Anixa adds 11% after dosing initiation in CAR-T ovarian cancer trial

• The shares of clinical-stage biotech Anixa Biosciences ( NASDAQ: ANIX ) jumped ~11% to reach the highest level since November on the announcement that the first patient received its chimeric antigen receptor T-cell (CAR-T) therapy in a Phase 1 clinical trial for ovarian cancer.
• The dose escalation study conducted with its partner Moffitt Cancer Center is designed to assess the early efficacy data, safety and maximum tolerated dose of the follicle-stimulating hormone receptor T-cells. The trial is expected to enroll up to 48 patients at the Moffitt Cancer Center.
• Anixa’s ( ANIX ) CAR-T approach used in the study is known as chimeric endocrine receptor T-cell (CER-T) therapy.
• It differs from traditional CAR-T drugs in that it specifically targets the follicle-stimulating hormone receptor (FSHR) which, according to research, is exclusively located in ovarian cells of healthy adult women.
• In March, Anixa ( ANIX ) announced initial plans to conduct the trial.

For further details see: